Analyst Price Target is $65.00
▲ +467.69% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for BioXcel Therapeutics in the last 3 months. The average price target is $65.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 467.69% upside from the last price of $11.45.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in BioXcel Therapeutics. This Buy consensus rating has held steady for over two years.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.